Agile Therapeutics (AGRX)
(Delayed Data from OTC)
$0.40 USD
0.00 (0.00%)
Updated Apr 26, 2024 02:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Agile Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 11 | 4 | 1 | 0 |
Cost Of Goods | 9 | 7 | 11 | 0 | 0 |
Gross Profit | 11 | 4 | -7 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 31 | 57 | 64 | 50 | 19 |
Income After Depreciation & Amortization | -20 | -53 | -71 | -49 | -19 |
Non-Operating Income | 7 | 26 | 0 | 0 | 0 |
Interest Expense | 1 | 3 | 4 | 3 | 0 |
Pretax Income | -14 | -30 | -75 | -52 | -19 |
Income Taxes | 0 | -5 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -25 | -75 | -52 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -25 | -75 | -52 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -18 | -49 | -69 | -49 | -19 |
Depreciation & Amortization (Cash Flow) | 1 | 4 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -20 | -53 | -71 | -49 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.16 | 0.43 | 0.05 | 0.04 | 0.03 |
Diluted EPS Before Non-Recurring Items | -9.84 | -92.00 | -1,540.00 | -1,220.00 | -760.00 |
Diluted Net EPS (GAAP) | -6.71 | -59.00 | -1,540.00 | -1,220.00 | -760.00 |
Fiscal Year end for Agile Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.62 | 6.66 | 5.50 | 3.81 |
Cost Of Goods | NA | 2.19 | 2.48 | 2.31 | 2.00 |
Gross Profit | NA | 1.42 | 4.19 | 3.20 | 1.81 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.47 | 8.19 | 8.32 | 8.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.05 | -4.00 | -5.12 | -6.71 |
Non-Operating Income | NA | -0.11 | 3.54 | 1.69 | 1.72 |
Interest Expense | NA | 0.30 | 0.34 | 0.37 | 0.40 |
Pretax Income | NA | -4.47 | -0.80 | -3.81 | -5.39 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.47 | -0.80 | -3.81 | -5.39 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.47 | -0.80 | -3.81 | -5.39 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 2.96 | 2.95 | 1.77 | 0.91 |
Diluted EPS Before Non-Recurring Items | NA | -1.46 | -1.47 | -3.10 | -7.76 |
Diluted Net EPS (GAAP) | NA | 1.62 | -0.27 | -2.15 | -5.91 |